natgillin/translations-raw huggingface dataset:
Almost a half of the patients treated with Zebinix experience side effects.
Do neželenih učinkov pride pri skoraj polovici bolnikov, ki jemljejo zdravilo Zebinix.
Almost all fevers were mild or moderate (<39.5°C) and transient (duration of ≤2 days). (See section 4.8).
Skoraj vsi primeri povišane telesne temperature so bili blagi ali zmerni (<39,5 °C) in prehodni (trajanje ≤2 dni). (Glejte poglavje 4.8).
Almost all HSR to abacavir include fever and/or rash .
Skoraj vse HSR na abakavir vključujejo povišano telesno temperaturo in/ali izpuščaj.
Almost all of these patients had also received medicines known as azathioprine or 6-mercaptopurine.
Skoraj vsi ti bolniki so prav tako prejemali zdravila znana kot azatioprin ali
Almost all patients had also received drugs known as azathioprine or 6-mercaptopurine in addition to TNF-blockers.
Skoraj vsi bolniki so poleg zaviralcev TNF prejeli tudi zdravilo azatioprin ali 6-merkaptopurin.
Almost all patients had also received drugs known as azathioprine or 6-mercaptopurine in addition to TNF-blockers..
Skoraj vsi ti bolniki so poleg zaviralcev TNF prejeli tudi zdravilo azatioprin ali 6-merkaptopurin.
Almost all patients had also received medicines known as azathioprine or 6-mercaptopurine in addition to TNF-blockers.
Skoraj vsi bolniki so poleg zaviralcev TNF prejeli tudi zdravilo azatioprin ali 6-merkaptopurin.
Almost all subjects (95%) were receiving cardiovascular medicinal products (beta blockers, ACE inhibitors, angiotensin II antagonists, calcium channel blockers, nitrates, diuretics, aspirin, statins, fibrates).
Skoraj vse osebe (95 %) so prejemale kardiovaskularna zdravila (zaviralce adrenergičnih receptorjev beta, zaviralce ACE, antagoniste angiotenzina II, zaviralce kalcijevih kanalčkov, nitrate, diuretike, acetilsalicilno kislino, statine, fibrate),
Almost all subjects (95%) were receiving cardiovascular medicinal products (beta blockers, ACE inhibitors, angiotensin II antagonists, calcium channel blockers, nitrates, diuretics, aspirin, statins, fibrates).
Skoraj vse osebe (95%) so prejemale kardiovaskularna zdravila (zaviralce adrenergičnih receptorjev beta, zaviralce ACE, antagoniste angiotenzina II, zaviralce kalcijevih kanalčkov, nitrate, diuretike, acetilsalicilno kislino, statine, fibrate).
Almost all subjects (95%) were receiving cardiovascular medicinal products (beta blockers, ACE inhibitors, angiotensin II antagonists, calcium channel blockers, nitrates, diuretics, aspirin, statins, fibrates).
Skoraj vsi preiskovanci (95%) so prejemali kardiovaskularna zdravila (zaviralce adrenergičnih receptorjev beta, zaviralce ACE, antagoniste angiotenzina II, zaviralce kalcijevih kanalčkov, nitrate, diuretike, acetilsalicilno kislino, statine, fibrate).
Almost all subjects with abnormal liver function tests were co-infected with Hepatitis B or C virus.
Skoraj vsi bolniki, pri katerih so testi jetrnih funkcij odstopali od normalnih vrednosti, so bili sočasno okuženi z virusom hepatitisa B ali C.
Almost all the patients in the main study had the virus cleared from their blood.
Pri skoraj vseh bolnikih, ki so sodelovali v glavni študiji, je bil virus odstranjen iz krvi.
Almost fainting (presyncope)
korajšnja omedlevica (presinkopa);
Almost half (45.8 %) of the RE-LY patients had a CrCL > 50-< 80 mL/min.
Pri skoraj polovici (45,8 %) bolnikov, ki jih je zajela raziskava RE-LY, je bil CrCl > 50 do < 80 ml/min.
aLOCF: Last observation (prior to or on the date of the first insulin up-titration, if needed) carried forward bAll randomised subjects who took at least one dose of double-blind study medicinal product during the short- term double-blind period cLeast squares mean adjusted for baseline value and presence of oral glucose-lowering medicinal product
aLOCF: Prenos zadnjega opažanja (pred ali na datum prvega povečanja odmerka insulina, če je bilo potrebno) [Last observation carried forward] bVsi randomizirani preiskovanci, ki so vzeli vsaj en odmerek dvojno slepljenega raziskovanega zdravila med kratkoročnim dvojno slepim obdobjem cPovprečje najmanjših kvadratov, prilagojeno za izhodiščno vrednost in prisotnost peroralnega antidiabetika
aLOCF: Last observation (prior to or on the date of the first insulin up-titration, if needed) carried forward bAll randomised subjects who took at least one dose of double-blind study medicinal product during the short-term double-blind period cLeast squares mean adjusted for baseline value and presence of oral glucose-lowering medicinal product
aLOCF: prenos zadnjega opažanja (pred ali na datum prvega zvišanja insulina, če je bilo potrebno) bVsi randomizirani preiskovanci, ki so prejeli vsaj en odmerek dvojno slepljenega raziskovanega zdravila med kratkoročnim dvojno slepim obdobjem cPovprečje najmanjših kvadratov, korigirano za izhodiščno vrednost in prisotnost peroralnega antidiabetika
aLOCF: Last observation (prior to rescue for rescued subjects) carried forward bAll randomised subjects who took at least one dose of double-blind study medication during the short-term double-blind period cLeast squares mean adjusted for baseline value
aLOCF: Prenos zadnjega opažanja (pred rešilnim zdravljenjem za preiskovance s takšnim zdravljenjem) [Last observation carried forward]) bVsi randomizirani preiskovanci, ki so prejeli vsaj en odmerek dvojno slepljenega raziskovanega zdravila v kratkoročnem dvojno slepem obdobju cPovprečje najmanjših kvadratov, prilagojeno za izhodiščno vrednost
aLOCF: Last observation carried forward bRandomised and treated subjects with baseline a cLeast squares mean adjusted for baseline value dNon-inferior to glipizide + metformin
a LOCF: Prenos zadnjega opažanja [Last observation carried forward] b Randomizirane in zdravljene osebe z izhodiščno in vsaj še eno poizhodiščno meritvijo učinkovitosti c Povprečje najmanjših kvadratov, prilagojeno za izhodiščno vrednost d Neinferiorno glede na glipizid + metformin
aLOCF: Last observation carried forward bRandomised and treated subjects with baseline and at cLeast squares mean adjusted for baseline value dNon-inferior to glipizide + metformin
aLOCF: prenos zadnjega opažanja [Last observation carried forward] bRandomizirani in zdravljeni preiskovanci z izhodiščno in vsaj še eno poizhodiščno meritvijo učinkovitosti cPovprečje najmanjših kvadratov, korigirano za izhodiščno vrednost dNeinferiorno v primerjavi s kombinacijo glipizid + metformin
aLOCF: Last observation carried forward bRandomised and treated subjects with baseline and at least 1 post-baseline efficacy measurement cLeast squares mean adjusted for baseline value dNon-inferior to glipizide + metformin
aLOCF: Prenos zadnjega opažanja [Last observation carried forward] bRandomizirane in zdravljene osebe z izhodiščno in vsaj še eno poizhodiščno meritvijo učinkovitosti cPovprečje najmanjših kvadratov, prilagojeno za izhodiščno vrednost dNeinferiorno glede na glipizid + metformin
Alogliptin 25 mg once daily (n=128)
Alogliptin 25 mg enkrat na dan (n=128)
Alogliptin 25 mg once daily with a thiazolidinedione  metformin or a sulphonylurea (n=195)
Alogliptin 25 mg enkrat na dan s tiazolidindionom  metformin ali sulfonilsečnina (n=195)
Alogliptin 25 mg once daily with metformin (n=203)
Alogliptin 25 mg enkrat na dan z metforminom (n=203)
Alogliptin 25 mg once daily with metformin vs a sulphonylurea + metformin
Alogliptin 25 mg enkrat na dan z metforminom v primerjavi s sulfonilsečnino + metforminom
Alogliptin 25 mg once daily with pioglitazone + metformin vs titrating pioglitazone + metformin
Alogliptin 25 mg enkrat na dan s pioglitazonom + metforminom v primerjavi s titracijo pioglitazona + metformina
Alogliptin 25 mg once daily with pioglitazone  metformin or a sulphonylurea (n=195)
Alogliptin 25 mg enkrat na dan s pioglitazonom  metformin ali sulfonilsečnina (n=195)
Alogliptin and metformin are substantially excreted by the kidney.
Alogliptin in metformin se v znatni meri izločata preko ledvic.
Alogliptin as add-on therapy to a sulphonylurea
Alogliptin kot dodatek k zdravljenju s sulfonilsečnino
Alogliptin as add-on therapy to a thiazolidinedione
Alogliptin kot dodatek k zdravljenju s tiazolidindionom
Alogliptin as add-on therapy to a thiazolidinedione with metformin
Alogliptin kot dodatek k zdravljenju s tiazolidindionom in z metforminom
Alogliptin as add-on therapy to insulin (with or without metformin)
Alogliptin kot dodatek k zdravljenju z insulinom (z metforminom ali brez)
Alogliptin as add-on therapy to metformin
Alogliptin kot dodatek k zdravljenju z metforminom
Alogliptin as add-on therapy to metformin with a thiazolidinedione
Alogliptin kot dodatek k zdravljenju z metforminom in s tiazolidindionom
Alogliptin as add-on therapy to metformin with insulin
Alogliptin kot dodatek k zdravljenju z metforminom in insulinom
Alogliptin as add-on therapy to pioglitazone
Alogliptin kot dodatek k zdravljenju s pioglitazonom
Alogliptin as add-on therapy to pioglitazone with metformin
Alogliptin kot dodatek k zdravljenju s pioglitazonom in z metforminom
alogliptin belongs to a group of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors).
Alogliptin spada v skupino zdravil, imenovano zaviralci DPP-4 (zaviralci dipeptidil-peptidaze-4).
Alogliptin has no or negligible influence on the ability to drive and use machines.
Alogliptin nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Alogliptin has not been studied in combination with sodium glucose cotransporter 2 (SGLT-2) inhibitors or glucagon like peptide 1 (GLP-1) analogues nor formally as triple therapy with metformin and a sulphonylurea.
Uporaba alogliptina ni bila raziskana v kombinaciji z zaviralci prenašalnega proteina za natrij in glukozo v ledvicah (SGLT-2; “sodium glucose cotransporter 2”), analogi glukagonu podobnega peptida 1 (GLP-1; “glucagon like peptide 1”), niti formalno v okviru trotirnega zdravljenja z metforminom in s sulfonilsečnino.
Alogliptin has not been studied in patients with severe hepatic impairment (Child-Pugh score >9) and is, therefore, not recommended for use in such patients (see sections 4.2, 4.3 and 5.2).
Pri bolnikih s hudo okvaro jeter (ocena po Child-Pugh-u > 9) uporabe alogliptina niso raziskovali, zato njegova uporaba pri teh bolnikih ni priporočljiva (glejte poglavja 4.2, 4.3 in 5.2).
Alogliptin is primarily excreted unchanged in the urine and metabolism by the cytochrome (CYP) P450 enzyme system is negligible (see section 5.2).
Alogliptin se primarno izloča z urinom v nespremenjeni obliki, presnova z encimskim sistemom citokroma (CYP) P450 pa je zanemarljiva (glejte poglavje 5.2).
alone
enkrat na dan
alone as basal insulin
amostojno kot bazalni insulin;
alone or in combination with other fat-lowering medicines in patients who cannot tolerate or cannot be given statins. adults and children aged 12 years and over who have ‘homozygous familial hypercholesterolaemia’ (a severe form of hypercholesterolaemia caused by a genetic abnormality inherited from both parents).
amostojno ali v kombinaciji z drugimi zdravili za zniževanje ravni maščob pri bolnikih, ki ne prenašajo ali ne smejo prejemati statinov; za zdravljenje odraslih in otrok, starejših od 12 let, ki imajo „homozigotno družinsko hiperholesterolemijo“ (hudo obliko hiperholesterolemije, ki jo povzroča genetska nepravilnost,
alone or together with the medicines pegylated liposomal doxorubicin or dexamethasone, for patients whose disease is worsening (progressive) after receiving at least one prior treatment and for whom blood stem cell transplantation was not successful or is unsuitable.
amostojno ali v kombinaciji s pegiliranim liposomskim doksorubicinom ali deksametazonom pri bolnikih, pri katerih je bolezen napredovala po tem, ko so prejeli vsaj eno predhodno vrsto zdravljenja in so jim že presadili krvotvorne matične celice ali presaditev krvotvornih matičnih celic pri njih ni mogoča
alone or together with the medicines pegylated liposomal doxorubicin or dexamethasone, for patients whose disease is worsening (progressive) after receiving at least one prior treatment and for whom blood stem cell transplantation was not successful or is unsuitable.
amostojno ali v kombinaciji s pegiliranim liposomskim doksorubicinom ali deksametazonom pri bolnikih, pri katerih je bolezen napredovala po tem, ko so prejeli vsaj eno predhodno vrsto zdravljenja in so jim že presadili krvotvorne matične celice ali presaditev krvotvornih matičnih celic pri njih ni mogoča;
alone or together with the medicines pegylated liposomal doxorubicin or dexamethasone, for patients whose disease is worsening (progressive) after receiving at least one prior treatment and for whom blood stem cell transplantation was not successful or is unsuitable.
amostojno ali v kombinaciji s pegiliranim liposomskim doksorubicinom ali deksametazonom pri bolnikih, pri katerih je bolezen napredovala po tem, ko so prejeli vsaj eno predhodno vrsto zdravljenja in so jim že presadili krvotvorne matične celice ali presaditev krvotvornih matičnih celic pri njih ni primerna.
alone)
Sakvinavir
Along with diet and exercise, this helps lower your blood sugar.
Vse to – skupaj z dieto in telesno dejavnostjo – pomaga znižati krvni sladkor.
Along with diet and exercise, this medicine helps lower your blood sugar.
Zdravilo ob dieti in telesni aktivnosti dodatno znižuje krvni sladkor.
Alopecia
Alopecija.
Alopecia
artritis
Alopecia
izpadanje las
Alopecia
Pogosti:
Alopecia
Slabost
Alopecia (G3/4: 10.9%)
alopecija (S 3/4: 10,9 %)
Alopecia (G3/4: 10.9%)
alopecija (S3/4: 10,9 %)
Alopecia (G3/4: 10.9%).
Alopecija (S3/4: 10,9 %)
Alopecia (G3/4: 10.9%).
Alopecija (S3/4: 4,0 %)
Alopecia (G3/4: 4.0%)
alopecija (S 3/4: 4,0 %)
Alopecia (G3/4: 4.0%)
alopecija (S3/4: 4,0 %)
Alopecia (G3/4: 4.0%).
alopecija (S 3/4: 4,0 %)
Alopecia (G3/4: 4.0%);
alopecija (S 3/4: 4,0 %), srbeč izpuščaj
Alopecia (G3/4: 4.0%);
Alopecija (S3/4: 10,9 %)
Alopecia (G3/4: 4.0%); Rash pruritic
alopecija (S 3/4: 4,0 %), srbeč izpuščaj
Alopecia (G3/4: 4.0%); Rash pruritic
alopecija (S3/4: 4,0 %), pruritičen izpuščaj
Alopecia (G3/4: 4.0%); Rash pruritic
alopecija (S3/4: 4,0 %), srbeč izpuščaj
Alopecia (G3/4: 4.0%); Rash pruritic;
alopecija (S3/4: 4,0 %), srbeč izpuščaj
Alopecia (G3/4: 6%); Nail disorders (G3/4: 2%)
Alopecija, eritem, izpuščaj, spremembe nohtov
Alopecia (G3/4: 6%); Nail disorders (G3/4: 2%)
roka/noga sindrom (S3/4: 24 %) alopecija (S3/4: 6 %), spremembe nohtov (S3/4: 2 %)
Alopecia (G3/4: <0.1%);
alopecija(S3/4:
Alopecia (hair loss)
alopecija (izpadanje las oziroma dlak);
Alopecia (persisting:
alopecija (persistentna:
alopecia (unusual hair loss or thinning), pruritus (itching)
alopecija (neobičajno izpadanje ali redčenje las), pruritus (srbenje);
Alopecia Acne Rosacea Eczema
alopecija akne rozacea ekcem
Alopecia Photosensitivity reaction
alopecija fotosenzibilnostna reakcija
Alopecia Pruritus Rash
alopecija pruritus izpuščaj
Alopecia related to study drug started or worsened during the follow-up period in 42 patients (7.9 %) in TAC arm and 30 patients (5.8 %) in FAC arm.
Alopecija, povezana z raziskovanim zdravilom, je nastala ali se je poslabšala med obdobjem spremljanja pri 42 bolnicah (7,9 %) v kraku TAC in pri 30 bolnicah (5,8 %) v kraku FAC.
Alopecia related to study drug started or worsened during the follow-up period in 42 patients (7.9%) in TAC arm and 30 patients (5.8%) in FAC arm.
Alopecija, povezana z raziskovanim zdravilom, je nastala ali se je poslabšala med obdobjem spremljanja pri 42 bolnicah (7,9 %) v kraku TAC in pri 30 bolnicah (5,8 %) v kraku FAC.
Alopecia related to stufy drug started or worsened during the follow-up period in 42 patients (7.9%) in TAC arm and 30 patients (5.8%) in FAC arm.
Alopecija, povezana z raziskovanim zdravilom, je nastala ali se je poslabšala med obdobjem spremljanja pri 42 bolnicah (7,9 %) v kraku TAC in pri 30 bolnicah (5,8 %) v kraku FAC.
Alopecia was evaluated as a potential safety signal with 23 cases which included close temporal relationship and positive dechallenge and rechallenge experience which support a causal relationship between Ganfort and Alopecia.
Alopecija je bila ocenjena kot potencialni varnostni signal z 23 primeri, ki so zajemali tesno časovno povezavo ter pozitiven odziv na prenehanje uporabe in ponovno uporabo, kar podpira vzročno povezavo med zdravilom Ganfort in alopecijo.
Alopecia was observed in >80% of the patients treated with Abraxane.
Alopecijo so opazili pri > 80 % bolnikov, ki so jemali zdravilo Abraxane.
Alopecia(G3/4: <0.1%);
alopecija(S3/4:
Alopecia*
alopecija
Alopecia** Dry skin Hyperhidrosis
alopecija** suha koža hiperhidroza
Alopecia, capillaritis, vasculitis
alopecija, kapilaritis, vaskulitis
Alopecia, capillaritis, vasculitis
Organski sistem
Alopecia, cutaneous vasculitis, injection site pain, rash
alopecija, kožni vaskulitis, bolečina na mestu vboda, izpuščaj
alopecia, dermatitis (including eczema), pruritus, acne, dry skin, urticaria, hyperhidrosis
alopecija, dermatitis (vključno z ekcemom), pruritus, akne, suha koža, urtikarija, čezmerno znojenje
Alopecia, dermatitis, pruritis, dry skin
alopecija, dermatitis, pruritus, suha koža
Alopecia, dry skin, eczema, lipoatrophy, pruritus, rash
alopecija, suha koža, ekcem, lipoatrofija, pruritus, izpuščaj
Alopecia, dry skin, hyperhidrosis, erythema, nail disorder, skin disorder
alopecija, suha koža, hiperhidroza, eritem, bolezni nohtov, bolezni kože
Alopecia, dry skin, hyperhidrosis, erythema, skin disorder, pruritus
alopecija, suha koža, hiperhidroza, eritem, bolezni kože, pruritus
Alopecia, dry skin, pruritus, rash
alopecija, suha koža, srbenje, izpuščaj
Alopecia, eczema, pruritus
alopecija, ekcem, pruritus
Alopecia, eczema, pruritus,
alopecija, ekcem, pruritus
alopecia, erythema, night sweats
alopecija, eritem, nočno znojenje
alopecia, erythema, night sweats
krvavitev iz penisa, hemospermija,
Alopecia, erythema, night sweats, pruritus
plešavost, eritem, nočno potenje, pruritus
Alopecia, hyperhidrosis, pruritic rash
Alopecija, hiperhidroza, pruritični izpuščaj
Alopecia, Nail disorder
alopecija, spremembe na nohtih
alopecia, new onset or worsening of psoriasis (including palmoplantar pustular psoriasis) and related conditions, dermatitis and eczema, sweat gland disorder, skin ulcer, photosensitivity, acne, skin discolouration, dry skin, nail and nail bed disorders
alopecija, nov pojav ali poslabšanje psoriaze (vključno s palmoplantarno pustulozno psoriazo) in z njo povezani simptomi, dermatitis in ekcem, motnje žlez znojnic, razjede kože, fotosenzitivna reakcija, akne, razbarvanost kože, suha koža, motnje nohtov in nohtne posteljice
alopecia, photosensitivity
alopecija, fotosenzibilnost
Alopecia, photosensitivity
alopecija, fotosenzitivnost
Alopecia, photosensitivity reactions
alopecija, fotosenzitivnostne reakcije
Alopecia, pruritus
izpadanje las, srbenje
Alopecia, pruritus*, dry skin*, rash*
alopecija, pruritus*, suha koža*, izpuščaj
Alopecia, pruritus*, skin dry*, rash*, sweating increased Psoriasis (new or aggravated)§, rash maculopapular, rash
alopecija, pruritus*, suha koža*, izpuščaj*, povečano
Alopecia, pruritus, night sweats, eczema
alopecija, srbečica, nočno potenje, ekcem
Alopecia, purpura, skin decolouration, hyperhidrosis, pruritus, rash, exanthema
alopecija, purpura, razbarvanje kože, čezmerno znojenje, srbenje, izpuščaj, eksantem
alopecia, purpura, skin discolouration, hyperhidrosis
alopecija, purpura, obarvanost kože, hiperhidroza
Alopecia, skin rash
alopecija, izpuščaj na koži
Alopecia,eczema, pruritus,
alopecija, ekcem, pruritus
Alopecia: Alopecia was reported in approximately 3% of patients treated with the monotherapy regimen, of which the majority was grade 1 alopecia.
Alopecija: O alopeciji so poročali pri približno 3 % bolnikov, zdravljenih z režimom monoterapije, pri čemer je pri večini šlo za alopecijo stopnje 1.
Alopecia; Erythema, Rash; Nail disorders
alopecija, eritem, izpuščaj, spremembe nohtov
Alopecia; Erythema; Rash; Nail
alopecija, eritem, izpuščaj, spremembe nohtov
Alopecia; Erythema; Rash; Nail disorders
alopecija, eritem, izpuščaj, spremembe nohtov
Alopecia; Nail disorders (severe 0.4%); Skin reaction (no severe)
alopecija, spremembe nohtov (hude 0,4 %), koţna reakcija (ne huda)
Alopecia; Nail disorders (severe 0.7%); Skin reaction (G3/4: 0.2%)
alopecija, spremembe nohtov (hude: 0,7 %), koţna reakcija (S3/4: 0,2 %)
Alopecia; Nail disorders (severe 0.7%); Skin reaction (G3/4: 0.2%)
premembe nohtov (hude: 0,7 %), koţna reakcija (S3/4: 0,2 %)
Alopecia; Nail disorders (severe: 0.4%); Skin reaction (no severe)
alopecija, spremembe nohtov (hude 0,4 %), kožna reakcija (nobene hude)
Alopecia; Skin reaction (G3/4: 5.9%); Nail disorders (severe: 2.6%)
alopecija, kožna reakcija (S3/4: 5,9 %), spremembe nohtov (hude 2,6 %)
alopecias, acne, sweating increased
alopecija, akne, močnejše znojenje
alosetron for the management of severe diarrhea
alosetron za obvladovanje hude driske,
alosetron for the management of severe diarrhoea
alosetron za obvladovanje hude driske,
Aloxi 250 micrograms solution for injection Palonosetron
Aloxi 250 mikrogramov raztopina za injiciranje palonosetron
Aloxi 250 micrograms solution for injection Palonosetron (as hydrochloride)
Aloxi 250 mikrogramov raztopina za injiciranje palonosetron (v obliki palonosetronijevega klorida)
Aloxi 250 micrograms solution for injection.
Aloxi 250 mikrogramov raztopina za injiciranje
Aloxi 500 micrograms soft capsules
Aloxi 500 mikrogramov mehke kapsule
Aloxi 500 micrograms soft capsules are light beige, opaque, oval, imprinted with black logo “AlO” and filled with a clear yellowish solution.
Aloxi 500 mikrogramov mehke kapsule so svetlo sivkastorjave, neprozorne, ovalne kapsule s črnim logotipom »AlO« in napolnjene z bistro rumenkasto tekočino.
Aloxi belongs to a group of medicines known as serotonin (5HT3) antagonists.
Zdravilo Aloxi spada v skupino zdravil, znanih pod imenom antagonisti serotoninskih 5-HT3 receptorjev.
Aloxi belongs to a group of medicines known as serotonin (5HT3) antagonists.
Zdravilo Aloxi spada v skupino zdravil, znanih pod imenom antagonisti serotoninskih 5HT3 receptorjev.
Aloxi can be taken with or without food.
Zdravilo Aloxi lahko jemljete skupaj s hrano ali brez nje.
Aloxi contains less than 1 mmol sodium (23 mg) per vial, i.e. essentially ‘sodium- free’.
Zdravilo Aloxi vsebuje manj kot 1 mmol (23 mg) natrija na vialo, kar v bistvu pomeni ‘brez natrija’.
Aloxi contains sorbitol (E420).
Zdravilo Aloxi vsebuje sorbitol (E420).
Aloxi is taken to prevent nausea and vomiting caused by chemotherapy.
Zdravilo Aloxi jemljete za preprečevanje slabosti in bruhanja, ki ju povzroča kemoterapija.
Aloxi is used for the prevention of nausea and vomiting associated with cancer chemotherapy in adult patients.
Zdravilo Aloxi se uporablja za preprečevanje slabosti in bruhanja pri kemoterapiji raka pri odraslih bolnikih.
Aloxi is used for the prevention of nausea and vomiting associated with cancer chemotherapy in adults, adolescents and children over one month of age.
Zdravilo Aloxi se uporablja za preprečevanje slabosti in bruhanja pri kemoterapiji raka pri odraslih bolnikih, mladostnikih in otrocih, starejših od enega meseca.
Aloxi may cause dizziness or tiredness.
Zdravilo Aloxi lahko povzroča omotico ali utrujenost.
Aloxi solution for injection is a clear, colourless solution and is supplied in a pack of one Type I glass vial with chlorobutyl siliconised rubber stopper and aluminium cap, which contains 5 ml of the solution.
Raztopina za injiciranje zdravila Aloxi je bistra, brezbarvna raztopina, na voljo je v pakiranju, v katerem je ena viala iz stekla tipa I z zamaškom iz klorobutilne silikonizirane gume in aluminijastim pokrovčkom, ki vsebuje 5 ml raztopine.
Aloxi will be given as a slow infusion into a vein.
Zdravilo Aloxi bodo dajali kot počasno infuzijo v veno.
Aloxi with food and drink
Zdravilo Aloxi skupaj s hrano in pijačo
ALPHA 1- ADRENORECEPTOR ANTAGONIST
ANTAGONISTI ALFA 1-ADRENERGIČNIH RECEPTORJEV
ALPHA 1-ADRENORECEPTOR ANTAGONIST
ANTAGONISTI ADRENERGIČNIH RECEPTORJEV ALFA 1
ALPHA 1-ADRENORECEPTOR ANTAGONIST
ANTAGONISTI ADRENERGIČNIH RECEPTORJEV ALFA-1
Alpha 1-adrenoreceptor antagonists
Antagonisti adrenergičnih receptorjev alfa-1
alpha 1-adrenoreceptor antagonists: alfuzosin
antagonisti adrenoreceptorja alfa 1: alfuzosin
alpha 1-adrenoreceptor antagonists: alfuzosin
antagonisti adrenoreceptorjev alfa 1: alfuzosin